Wyeth R&D President Robert Ruffolo: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
With Wyeth’s NDA for Torisel pending at FDA April 5, exec outlines Wyeth’s early-stage oncology pipeline in an interview with “The Pink Sheet” DAILY.
You may also be interested in...
Wyeth’s Torisel To Launch In July Following FDA Approval
Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.
Wyeth’s Torisel To Launch In July Following FDA Approval
Renal cell carcinoma treatment will compete with Bayer/Onyx’s Nexavar and Pfizer’s Sutent.
Torisel Action Date Extended To July 5
FDA will use extension to examine new tumor evaluation information submitted by Wyeth.